CN109265480B - 一种高纯度替诺福韦艾拉酚胺杂质taf-y的制备方法 - Google Patents
一种高纯度替诺福韦艾拉酚胺杂质taf-y的制备方法 Download PDFInfo
- Publication number
- CN109265480B CN109265480B CN201811246267.3A CN201811246267A CN109265480B CN 109265480 B CN109265480 B CN 109265480B CN 201811246267 A CN201811246267 A CN 201811246267A CN 109265480 B CN109265480 B CN 109265480B
- Authority
- CN
- China
- Prior art keywords
- taf
- impurity
- tenofovir alafenamide
- adenine
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 title claims abstract description 40
- 229960004946 tenofovir alafenamide Drugs 0.000 title claims abstract description 40
- 239000012535 impurity Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 229930024421 Adenine Natural products 0.000 claims abstract description 24
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960000643 adenine Drugs 0.000 claims abstract description 24
- -1 (phenoxy phosphinyl) methoxy Chemical group 0.000 claims abstract description 20
- 239000012046 mixed solvent Substances 0.000 claims abstract description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 238000005886 esterification reaction Methods 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims abstract description 4
- 239000011230 binding agent Substances 0.000 claims abstract description 4
- 238000001953 recrystallisation Methods 0.000 claims abstract description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 33
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 22
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 239000012043 crude product Substances 0.000 claims description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000005660 chlorination reaction Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000012044 organic layer Substances 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000012320 chlorinating reagent Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000012839 conversion disease Diseases 0.000 abstract 1
- 239000013558 reference substance Substances 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 4
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 101100098709 Caenorhabditis elegans taf-1 gene Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- LDEKQSIMHVQZJK-AZFZMOAFSA-N propan-2-yl (2s)-2-[[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate Chemical compound O([C@H](C)CN1C2=NC=NC(N)=C2N=C1)CP(=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1 LDEKQSIMHVQZJK-AZFZMOAFSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
Abstract
本发明公开了一种高纯度替诺福韦艾拉酚胺杂质TAF‑Y的制备方法,该制备方法包括将9‑[(R)‑2‑[[(苯氧基氧膦基)甲氧基]丙基]]腺嘌呤(TAF‑M1)通过氯代,得到9‑[(R)‑2‑[[(苯氧基氯膦酰基)甲氧基]丙基]]腺嘌呤,在不使用任何溶剂和缚酸剂的条件下,直接与苯酚酯化反应得到替诺福韦艾拉酚胺杂质TAF‑Y粗品,最后经由混合溶剂进行一次重结晶操作,即可得到高纯度的替诺福韦艾拉酚胺杂质TAF‑Y纯品。本发明的制备方法具有合成路线简短、操作简单、反应转化率高、所得杂质产物纯度较高(HPLC纯度98%以上)、可应用于对照品研究等特点。
Description
技术领域
本发明属于药学领域,具体的涉及一种替诺福韦艾拉酚胺杂质TAF-Y的制备方法。
背景技术
替诺福韦艾拉酚胺(Tenofovir alafenamide,(TAF)),化学名9-[(R)-2-[[[[(S)-1-(异丙氧羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤,是一种新型的核苷类逆转录酶抑制剂(NIHI),由吉利德公司研发;与吉利德的另一种抗病毒药物替诺福韦酯(TDF)相比,仅为后者的十分之一剂量就能达到极好的抗病毒效果。2016年11月,美国FDA批准其上市,用于慢性乙型肝炎患者的治疗,未来,TAF将会是TDF的替代药物。
目前,TAF的主要制备路线是以(R)-替诺福韦为原料,与亚磷酸三苯酯反应得9-[(R)-2-[[(苯氧基氧膦基)甲氧基]丙基]]腺嘌呤,经过氯代、与L-丙氨酸异丙酯反应得9-[(R)-2-[[(R,S)-[[(S)-1-(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤,拆分后得9-[(R)-2-[[(S)-[[(S)-1-(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤(VIII),最后经成盐得富马酸替诺福韦酯。
合成工艺路线如下:
在合成TAF-1的中,会产生一个关键的杂质9-[(R)-2-[[(S)-[二-(苯氧基)氧膦基]甲氧基]丙基]腺嘌呤(TAF-Y),结构式如下:
该杂质的控制对替诺福韦艾拉酚胺合成工艺的研究具有重要意义。专利CN105330700 A中报道了替诺福韦艾拉酚胺杂质TAF-Y的一种制备方法,但是该制备方法收率太低,且需要柱层析纯化,操作复杂;专利WO 2015/161781 A1中报道了作为替诺福韦艾拉酚胺的中间体,合成9-[(R)-2-[[(S)-[二-(苯氧基)氧膦基]甲氧基]丙基]腺嘌呤的方法,合成工艺中需要使用二氯甲烷做溶剂且需要加入三乙胺等缚酸剂,该合成路线转化率低,杂质较多,收率较低。
发明内容
以下是对本文详细描述的主题的概述。本概述并非是为了限制权利要求的保护范围。
本发明的目的在于提供一种高纯度替诺福韦艾拉酚胺杂质TAF-Y的制备方法。
在本发明的实施方案中,本发明提供了一种高纯度替诺福韦艾拉酚胺杂质TAF-Y的制备方法,该制备方法包括如下步骤:
(1)以9-[(R)-2-[[(苯氧基氧膦基)甲氧基]丙基]]腺嘌呤(即TAF-M1)为原料,与氯代试剂进行氯代反应,得到9-[(R)-2-[[(苯氧基氯膦酰基)甲氧基]丙基]]腺嘌呤;
(2)将步骤(1)得到的9-[(R)-2-[[(苯氧基氯膦酰基)甲氧基]丙基]]腺嘌呤直接与苯酚进行酯化反应,制得替诺福韦艾拉酚胺杂质TAF-Y粗品;由混合溶剂对该替诺福韦艾拉酚胺杂质TAF-Y粗品进行一次重结晶,即可得到高纯度的替诺福韦艾拉酚胺杂质TAF-Y。
在一些实施方案中,本发明提供的替诺福韦艾拉酚胺杂质TAF-Y的制备方法,其中,步骤(1)中所述氯代试剂是二氯亚砜。
在本发明的实施方案中,本发明提供的替诺福韦艾拉酚胺杂质TAF-Y的制备方法,其中,步骤(2)所述的酯化反应是在在无任何溶剂和缚酸剂的条件下进行的。
在一些实施方案中,本发明提供的替诺福韦艾拉酚胺杂质TAF-Y的制备方法,其中,所述步骤(2)中苯酚的用量是9-[(R)-2-[[(苯氧基氧膦基)甲氧基]丙基]]腺嘌呤(TAF-M1)质量的2.0~10.0倍,优选为3.0倍。
在一些实施方案中,本发明提供的替诺福韦艾拉酚胺杂质TAF-Y的制备方法,其中,所述步骤(2)中所述的混合溶剂为甲苯与乙腈的混合溶剂、异丙醇与乙腈的混合溶剂、四氢呋喃与甲苯的混合溶剂、或二甲亚砜与四氢呋喃混合溶剂,优选地,为甲苯与乙腈的混合溶剂。这里,甲苯与乙腈的体积比为2~20:1,优选地,为4:1;异丙醇与乙腈的体积比为2~20:1,优选地,为4:1;四氢呋喃与甲苯的体积比为2~20:1,优选地,为4:1;或二甲亚砜与四氢呋喃的体积比为2~20:1,优选地,为4:1。
在一些实施方案中,本发明提供的替诺福韦艾拉酚胺杂质TAF-Y的制备方法,其中,步骤(2)所述高纯度的替诺福韦艾拉酚胺杂质TAF-Y的HPLC纯度为98%以上。
在本发明一种实施方案中,本发明提供了一种替诺福韦艾拉酚胺杂质TAF-Y的制备方法,该制备方法包括如下步骤:
(1)9-[(R)-2-[[(苯氧基氧膦基)甲氧基]丙基]]腺嘌呤室温下加入乙腈,缓慢滴加氯化亚砜,升温至70℃搅拌2~3h,反应完全后,浓缩,得9-[(R)-2-[[(苯氧基氯膦酰基)甲氧基]丙基]]腺嘌呤浓缩物;
(2)将步骤(1)得到的9-[(R)-2-[[(苯氧基氯膦酰基)甲氧基]丙基]]腺嘌呤浓缩物加入预热至80℃的苯酚中,控温80℃搅拌12h,反应结束降至室温;体系中加入纯化水和二氯甲烷,搅拌分层,有机层用碳酸钾溶液和纯化水洗涤各洗涤一次,干燥,浓缩,得到替诺福韦艾拉酚胺杂质TAF-Y粗品;将该替诺福韦艾拉酚胺杂质TAF-Y粗品室温下加入体积比为1:4的乙腈与甲苯混合溶剂,搅拌升温至60℃体系溶清,缓慢降温至-5℃,搅拌2h,过滤,干燥,得到白色固体替诺福韦艾拉酚胺杂质TAF-Y。
本发明的其它特征和优点将在随后的说明书中阐述,并且,部分地从说明书中变得显而易见,或者通过实施本发明而了解。本发明的目的和其他优点可通过在说明书、权利要求书中所特别指出的结构来实现和获得。
具体实施方式
下面通过实施例来进一步描述本发明的技术方案,这些实施例为示例性的,不构成对本发明保护范围的限定。本领域的技术人员,在本发明的教导下,根据现有技术而对其中技术特征进行等同替换仍属于本发明的保护范围内。
在本申请的实施例中,涉及ESI、NMR和HPLC检测条件如下:
质谱/高分辨质谱(MS/HRMS)
仪器:Agilent 1260-6230TOF LC-MS质谱仪
溶剂:甲醇
离子化方式:ESI(+),120V;ESI(-),120V
核磁共振谱(NMR):BRUKER AV-400型核磁共振仪
溶剂:DMSO-d6
温度:303K
内标:TMS
HPLC检测条件:
照高效液相色谱法(中国药典2015版四部通则0512)测定,用十八烷基硅烷键合硅胶为填充剂;
以20mmol/L磷酸二氢钾水溶液(用氢氧化钾试液调节pH至6.5)-乙腈-甲醇(950:15:35)为流动相A,
以乙腈-甲醇(3:7)为流动相B,梯度洗脱;流速为每分钟1.0ml,柱温为35℃,检测波长为260nm。
实施例1
替诺福韦艾拉酚胺杂质TAF-Y粗品的制备
将1g 9-[(R)-2-[[(苯氧基氧膦基)甲氧基]丙基]]腺嘌呤置于50mL三颈瓶内中,室温下加入15ml乙腈,缓慢滴加0.64g氯化亚砜,升温至70℃搅拌2~3h,反应完全后,浓缩,浓缩物加入预热至80℃的3.0g苯酚中,控温80℃搅拌12h,反应结束降至室温,体系中加入纯化水15ml和二氯甲烷15ml,搅拌分层,有机层用10%的碳酸钾溶液15ml和纯化水15ml洗涤各洗涤一次,干燥,浓缩,得到1.2g浓缩物,为替诺福韦艾拉酚胺杂质TAF-Y粗品,HPLC纯度89%。
实施例2
替诺福韦艾拉酚胺杂质TAF-Y的制备
1.2g油状物替诺福韦艾拉酚胺杂质TAF-Y粗品,置于50mL三颈瓶内中,室温下加入2ml乙腈和8ml甲苯,搅拌升温至60℃体系溶清,缓慢降温至-5℃,搅拌2h,过滤,干燥,得到白色固体替诺福韦艾拉酚胺杂质TAF-Y精品0.95g,总收率78.5%,HPLC纯度99%。
1H-NMR(400Mz,DMSO-d6)δ:1.15(d,3H,CH3),3.03(m,1H,CH2CH),3.81(m,2H,OCH2P),3.75~4.02(m,2H,CH2CH),6.86(s,2H,NH2),7.16~7.36(m,10H,2×C6H5),8.05(s,1H,H-2),8.14(s,1H,H-8)
MS(ESI):440.6[M+H]+
虽然本申请所揭露的实施方式如上,但所述的内容仅为便于理解本申请而采用的实施方式,并非用以限定本申请。任何本申请所属领域内的技术人员,在不脱离本申请所揭露的精神和范围的前提下,可以在实施的形式及细节上进行任何的修改与变化,但本申请的专利保护范围,仍须以所附的权利要求书所界定的范围为准。
Claims (4)
1.一种替诺福韦艾拉酚胺杂质TAF-Y的制备方法,该制备方法包括如下步骤:
(1)以9-[(R)-2-[[(苯氧基氧膦基)甲氧基]丙基]]腺嘌呤(即TAF-M1)为原料,与氯代试剂进行氯代反应,得到9-[(R)-2-[[(苯氧基氯膦酰基)甲氧基]丙基]]腺嘌呤;
(2)将步骤(1)得到的9-[(R)-2-[[(苯氧基氯膦酰基)甲氧基]丙基]]腺嘌呤直接与苯酚进行酯化反应,制得替诺福韦艾拉酚胺杂质TAF-Y粗品;由混合溶剂对该替诺福韦艾拉酚胺杂质TAF-Y粗品进行一次重结晶,得到HPLC纯度为98%以上的替诺福韦艾拉酚胺杂质TAF-Y;
其中,步骤(1)中所述氯代试剂是二氯亚砜;
步骤(2)所述的酯化反应是在无任何溶剂和缚酸剂的条件下进行的;
所述步骤(2)中苯酚的用量是9-[(R)-2-[[(苯氧基氧膦基)甲氧基]丙基]]腺嘌呤(TAF-M1)质量的2.0~10.0倍;
所述步骤(2)中所述的混合溶剂为甲苯与乙腈的混合溶剂,甲苯与乙腈的体积比为2~20:1。
2.如权利要求1所述的制备方法,其中,所述步骤(2)中苯酚的用量是9-[(R)-2-[[(苯氧基氧膦基)甲氧基]丙基]]腺嘌呤(TAF-M1)质量的3.0倍。
3.如权利要求1或2所述的制备方法,其中,所述步骤(2)中甲苯与乙腈的体积比为4:1。
4.一种替诺福韦艾拉酚胺杂质TAF-Y的制备方法,该制备方法包括如下步骤:
(1)9-[(R)-2-[[(苯氧基氧膦基)甲氧基]丙基]]腺嘌呤室温下加入乙腈,缓慢滴加氯化亚砜,升温至70℃搅拌2~3h,反应完全后,浓缩,得9-[(R)-2-[[(苯氧基氯膦酰基)甲氧基]丙基]]腺嘌呤浓缩物;
(2)将步骤(1)得到的9-[(R)-2-[[(苯氧基氯膦酰基)甲氧基]丙基]]腺嘌呤浓缩物加入预热至80℃的苯酚中,控温80℃搅拌12h,反应结束降至室温;体系中加入纯化水和二氯甲烷,搅拌分层,有机层用碳酸钾溶液和纯化水洗涤各洗涤一次,干燥,浓缩,得到替诺福韦艾拉酚胺杂质TAF-Y粗品;将该替诺福韦艾拉酚胺杂质TAF-Y粗品室温下加入体积比为1:4的乙腈与甲苯混合溶剂,搅拌升温至60℃体系溶清,缓慢降温至-5℃,搅拌2h,过滤,干燥,得到白色固体替诺福韦艾拉酚胺杂质TAF-Y;其中,所述苯酚的用量是9-[(R)-2-[[(苯氧基氧膦基)甲氧基]丙基]]腺嘌呤(TAF-M1)质量的3.0倍。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811246267.3A CN109265480B (zh) | 2018-10-24 | 2018-10-24 | 一种高纯度替诺福韦艾拉酚胺杂质taf-y的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811246267.3A CN109265480B (zh) | 2018-10-24 | 2018-10-24 | 一种高纯度替诺福韦艾拉酚胺杂质taf-y的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109265480A CN109265480A (zh) | 2019-01-25 |
CN109265480B true CN109265480B (zh) | 2021-08-13 |
Family
ID=65194099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811246267.3A Active CN109265480B (zh) | 2018-10-24 | 2018-10-24 | 一种高纯度替诺福韦艾拉酚胺杂质taf-y的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109265480B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111018914A (zh) * | 2019-12-16 | 2020-04-17 | 株洲千金药业股份有限公司 | 一种富马酸替诺福韦二吡呋酯杂质的制备方法 |
CN111239285B (zh) * | 2020-02-20 | 2020-10-09 | 北京阳光诺和药物研究有限公司 | 一种替诺呋韦艾拉酚胺中基因毒性杂质的含量检测方法 |
CN112782311B (zh) * | 2020-12-30 | 2022-12-27 | 南京百泽医药科技有限公司 | 一种富马酸丙酚替诺福韦中l-丙氨酸异丙酯的hplc测定方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105330700A (zh) * | 2015-12-17 | 2016-02-17 | 中国药科大学 | 富马酸替诺福韦艾拉酚胺杂质的制备方法 |
CN107021984A (zh) * | 2017-04-28 | 2017-08-08 | 福建广生堂药业股份有限公司 | 一种taf核苷衍生物的制备方法及其中间体 |
-
2018
- 2018-10-24 CN CN201811246267.3A patent/CN109265480B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105330700A (zh) * | 2015-12-17 | 2016-02-17 | 中国药科大学 | 富马酸替诺福韦艾拉酚胺杂质的制备方法 |
CN107021984A (zh) * | 2017-04-28 | 2017-08-08 | 福建广生堂药业股份有限公司 | 一种taf核苷衍生物的制备方法及其中间体 |
Also Published As
Publication number | Publication date |
---|---|
CN109265480A (zh) | 2019-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109265480B (zh) | 一种高纯度替诺福韦艾拉酚胺杂质taf-y的制备方法 | |
EA005892B1 (ru) | Способ получения противораковых соединений | |
US10913756B2 (en) | Phosphoramidate compound and preparation method and crystal thereof | |
CN111793101B (zh) | C-核苷化合物的合成方法 | |
CN114014872B (zh) | 青蒿琥酯衍生物及其制备方法和应用 | |
CN111704646A (zh) | 甾体类化合物及其制备方法和用途 | |
Han et al. | Studies on the mechanism of mitomycin C (1) electrophilic transformations: structure-reactivity relationships | |
CN114846008B (zh) | 具有果糖激酶(khk)抑制作用的嘧啶类化合物 | |
CN112110897B (zh) | 一种氘代克里唑蒂尼及其衍生物的制备方法 | |
CN115947717B (zh) | 一类kif18a抑制剂 | |
CN108358884B (zh) | 一种坦螺旋霉素(17-aag)中间体的制备方法 | |
CN115043826B (zh) | 一类青藤碱呋咱衍生物及其制备方法和应用 | |
CN116867791A (zh) | 三并环类化合物及其应用 | |
CN101805339B (zh) | 一种制备恩替卡韦化合物的方法 | |
CN112028778A (zh) | 一种盐酸溴己新工艺杂质定位对照品的合成和杂质鉴定方法 | |
CN111943959A (zh) | 一种jak抑制剂的合成方法 | |
CN112194602A (zh) | 一种氯胺酮及其衍生物和中间体的合成方法 | |
CN110981911A (zh) | 一种替诺福韦艾拉酚胺的制备方法 | |
CN114945576B (zh) | 氘代噻吩并吡啶类化合物 | |
CN114478509B (zh) | 五元杂环取代的苯甲酰胺类化合物及其制备方法与应用 | |
CN114436925B (zh) | 间二苯酚醚类化合物及其制备方法与应用 | |
CN114933601A (zh) | 汉防己甲素衍生物及其制备方法和应用 | |
WO2023230236A1 (en) | Process for preparing jak inhibitors and intermediates thereof | |
JPH0381258A (ja) | 新規なドーパ誘導体 | |
Schulze et al. | The structure of McN-5652 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |